Pharmacy World and Science

, Volume 25, Issue 3, pp 94–97 | Cite as

Drug interaction management

  • P.D. Hansten


Although thousands of articles on drug interactions have been published and numerous computerized screening systems have been developed, patients continue to suffer from adverse drug interactions. Possible methods for reducing the risk of drug interactions include improving the knowledge of health care providers, improving computerized screening systems, providing information on patient risk factors, increased use of pharmacogenetic information, more attention to drug administration risk factors, and improving patient education on drug interactions.

Computerized screening Drug interactions Drug interaction management Pharmacogenomics Prescribing errors Risk assessment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000.Google Scholar
  2. 2.
    Hansten PD, Horn JR. Drug interactions analysis and management, St. Louis, Missouri, Facts & Comparisons, 2002.Google Scholar
  3. 3.
    Hazlet TK, Lee TA, Hansten PD, Horn, JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 200–4.Google Scholar
  4. 4.
    Chrischilles EA, Fulda TR, Byrns PJ, Winckler SC, Rupp MT, Chui MA. The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc 2002; 42: 439–48.Google Scholar
  5. 5.
    Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343–70.Google Scholar
  6. 6.
    Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40:568–73.Google Scholar
  7. 7.
    Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc 2001; 41: 161–165.Google Scholar
  8. 8.
    Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc 2001; 41: 159–60.Google Scholar
  9. 9.
    Doucet J, Chassange P, Trivalle C, Landrin I, Pauty MD, Kadri N et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996; 44: 944–8.Google Scholar
  10. 10.
    Orloff DG. Label changes for Simvastatin (Zocor). US Food and Drug Administration, 2002.Google Scholar
  11. 11.
    Mulder AB, van Lijf HJ, Bon MA, van den Bergh FA, Touw DJ, Neef C, Vermes I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70: 546–51.Google Scholar
  12. 12.
    Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3–hydroxy-3–methylglutaril coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66: 358–66.Google Scholar
  13. 13.
    Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 3 97–402.Google Scholar
  14. 14.
    Sugimoto K, Ohmori M, Tsuroka S, Nishiki K, Kawaguchi A, Harada K et al. Different effects of St. John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518–24.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • P.D. Hansten
    • 1
  1. 1.University of WashingtonSeattleUSA

Personalised recommendations